BioMark Diagnostics Inc.
BUX
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.28% | -22.91% | 40.39% | 11.90% | -56.96% |
| Total Depreciation and Amortization | -54.08% | 278.23% | -1.88% | 0.95% | -43.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -62.07% | 35.51% | -77.21% | -43.71% | 2,389.55% |
| Change in Net Operating Assets | 105.10% | -615.88% | -76.14% | 1,295.87% | -75.65% |
| Cash from Operations | 34.42% | -132.23% | -41.54% | 59.13% | -47.33% |
| Capital Expenditure | -100.00% | -- | -- | 100.00% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -194,471.43% | -- | -- | 100.00% | -100.00% |
| Total Debt Issued | 0.00% | -19.04% | 23.52% | 0.00% | 0.00% |
| Total Debt Repaid | -8.62% | -42.62% | -4.81% | 25.10% | 59.09% |
| Issuance of Common Stock | -- | 1,047.57% | 400.78% | -86.36% | 6.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -103.64% | 1,038.40% | 895.43% | -92.22% | 409.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -198.39% | 4,231.17% | 149.23% | -598.21% | 90.34% |